In 2014, radioimmunotherapy was initially approved in Austria. Therefore, radioimmuno-therapy is considered a new method in the treatment of CD20 positive follicular Non-Hodgkin lymphoma. In practice, this kind of treatment method is still used as a second or third line therapy option.
The topic and aim of this research is to examine the processes of radioimmunotherapy and demonstrating the fields of responsibility of radiation therapists. Furthermore this paper describes immunotherapy plans and the patients therapy path during their treatment.
This paper discusses the research questions, why radiation therapists are not mentioned in professional literature regarding radioimmunotherapy and why it is not used as first therapy option during the patients treatment.
Databases, like PubMed and Science Direct were used to depict those research questions.